In this study, VK2 directly binds to HSD17B4 to inhibit the proliferation of HCC cells by inhibiting the activation of Akt and MEK/ERK signaling pathways, leading to decreased STAT3 activation (Figure 5). Here, STAT3 is linked to hepatocellular carcinoma.